TAS2R41 and cutaneous melanoma: Specifically, nonsilent mutation rates in skin melanoma were approximately 7% for TAS1R2 and TAS2R60, 6% for TAS2R38, and 4.5% for TAS2R41. In liver hepatocellular carcinoma, the 3 TAS1Rs were each mutated in about 3% of individuals.